![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Departments of Molecular Pharmacology (K.J.V., E.R.G., G.W., M.H., L.S.) and Computational, Combinatorial, and Medicinal Chemistry (L.T., Q.S.), Purdue Pharma Discovery Research, Cranbury, New Jersey; and Discovery Support (Y.R.), Purdue Pharma, Ardsley, New York
Vanilloids such as capsaicin have algesic properties and seem to mediate their effects via activation of the vanilloid receptor 1 (VR1), a ligand-gated ion channel highly expressed on primary nociceptors. Although blockade of capsaicin-induced VR1 activation has been demonstrated in vitro and in vivo with the antagonist capsazepine, efficacy in rat models of chronic pain has not been observed with this compound. Here, we describe the in vitro pharmacology of a highly potent VR1 antagonist, N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC). Similar to capsazepine, this compound inhibits capsaicin-induced activation of rat VR1 with an IC50 value of 35 nM. Interestingly however, BCTC also potently inhibits acid-induced activation of rat VR1 (IC50 value of 6.0 nM), whereas capsazepine is inactive. Similarly, in the rat skin-nerve preparation both BCTC and capsazepine block capsaicin-induced activation, whereas the response to acidification is inhibited by BCTC, but not by capsazepine. Specificity for VR1 was demonstrated against 63 other receptor, enzyme, transporter, and ion channel targets. BCTC was orally bioavailable in the rat, demonstrating a plasma half-life of 
1 h and significant penetration into the central nervous system. Thus, BCTC is a high potency, selective VR1 antagonist that, unlike capsazepine, has potent blocking effects on low pH-induced activation of rat VR1. These properties make it a more suitable candidate than capsazepine for testing the role played by VR1 in rat models of human disease.
Address correspondence to: Dr. Kenneth J. Valenzano, 6 Cedarbrook Dr., Cranbury, NJ 08512. E-mail: ken.valenzano{at}pharma.com
This article has been cited by other articles:
|
|
 |
|
  A. Dhaka, V. Uzzell, A. E. Dubin, J. Mathur, M. Petrus, M. Bandell, and A. Patapoutian TRPV1 Is Activated by Both Acidic and Basic pH J. Neurosci., January 7, 2009; 29(1): 153 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. U. De Schepper, B. Y. De Winter, L. Van Nassauw, J.-P. Timmermans, A. G. Herman, P. A. Pelckmans, and J. G. De Man TRPV1 receptors on unmyelinated C-fibres mediate colitis-induced sensitization of pelvic afferent nerve fibres in rats J. Physiol., November 1, 2008; 586(21): 5247 - 5258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Surowy, T. R. Neelands, B. R. Bianchi, S. McGaraughty, R. El Kouhen, P. Han, K. L. Chu, H. A. McDonald, M. Vos, W. Niforatos, et al. (R)-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal Activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-Evoked Firing of Spinal Dorsal Horn Neurons in Vivo J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 879 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Escalera, C. A. von Hehn, B. F. Bessac, M. Sivula, and S.-E. Jordt TRPA1 Mediates the Noxious Effects of Natural Sesquiterpene Deterrents J. Biol. Chem., August 29, 2008; 283(35): 24136 - 24144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Fajardo, V. Meseguer, C. Belmonte, and F. Viana TRPA1 Channels Mediate Cold Temperature Sensing in Mammalian Vagal Sensory Neurons: Pharmacological and Genetic Evidence J. Neurosci., July 30, 2008; 28(31): 7863 - 7875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. U. De Schepper, J. G. De Man, N. E. Ruyssers, A. Deiteren, L. Van Nassauw, J.-P. Timmermans, W. Martinet, A. G. Herman, P. A. Pelckmans, and B. Y. De Winter TRPV1 receptor signaling mediates afferent nerve sensitization during colitis-induced motility disorders in rats Am J Physiol Gastrointest Liver Physiol, January 1, 2008; 294(1): G245 - G253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Cadiou, M. Studer, N. G. Jones, E. St. J. Smith, A. Ballard, S. B. McMahon, and P. A. McNaughton Modulation of Acid-Sensing Ion Channel Activity by Nitric Oxide J. Neurosci., November 28, 2007; 27(48): 13251 - 13260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhattacharya, B. P. Scott, N. Nasser, H. Ao, M. P. Maher, A. E. Dubin, D. M. Swanson, N. P. Shankley, A. D. Wickenden, and S. R. Chaplan Pharmacology and Antitussive Efficacy of 4-(3-Trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic Acid (5-Trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a Transient Receptor Potential Vanilloid 1 Antagonist in Guinea Pigs J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 665 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Gavva, A. W. Bannon, D. N. Hovland Jr., S. G. Lehto, L. Klionsky, S. Surapaneni, D. C. Immke, C. Henley, L. Arik, A. Bak, et al. Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gunthorpe, S. L. Hannan, D. Smart, J. C. Jerman, S. Arpino, G. D. Smith, S. Brough, J. Wright, J. Egerton, S. C. Lappin, et al. Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1183 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Malkia, R. Madrid, V. Meseguer, E. de la Pena, M. Valero, C. Belmonte, and F. Viana Bidirectional shifts of TRPM8 channel gating by temperature and chemical agents modulate the cold sensitivity of mammalian thermoreceptors J. Physiol., May 15, 2007; 581(1): 155 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Gavva, A. W. Bannon, S. Surapaneni, D. N. Hovland Jr, S. G. Lehto, A. Gore, T. Juan, H. Deng, B. Han, L. Klionsky, et al. The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation J. Neurosci., March 28, 2007; 27(13): 3366 - 3374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Madrid, T. Donovan-Rodriguez, V. Meseguer, M. C. Acosta, C. Belmonte, and F. Viana Contribution of TRPM8 Channels to Cold Transduction in Primary Sensory Neurons and Peripheral Nerve Terminals J. Neurosci., November 29, 2006; 26(48): 12512 - 12525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Klionsky, R. Tamir, B. Holzinger, X. Bi, J. Talvenheimo, H. Kim, F. Martin, J.-C. Louis, J. J. S. Treanor, and N. R. Gavva A Polyclonal Antibody to the Prepore Loop of Transient Receptor Potential Vanilloid Type 1 Blocks Channel Activation J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 192 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lazar, D. C. Braun, A. Toth, Y. Wang, L. V. Pearce, V. A. Pavlyukovets, P. M. Blumberg, S. H. Garfield, S. Wincovitch, H.-K. Choi, et al. Kinetics of Penetration Influence the Apparent Potency of Vanilloids on TRPV1 Mol. Pharmacol., April 1, 2006; 69(4): 1166 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Gavva, R. Tamir, L. Klionsky, M. H. Norman, J.-C. Louis, K. D. Wild, and J. J. S. Treanor Proton Activation Does Not Alter Antagonist Interaction with the Capsaicin-Binding Pocket of TRPV1 Mol. Pharmacol., December 1, 2005; 68(6): 1524 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Weil, S. E. Moore, N. J. Waite, A. Randall, and M. J. Gunthorpe Conservation of Functional and Pharmacological Properties in the Distantly Related Temperature Sensors TRVP1 and TRPM8 Mol. Pharmacol., August 1, 2005; 68(2): 518 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. El Kouhen, C. S. Surowy, B. R. Bianchi, T. R. Neelands, H. A. McDonald, W. Niforatos, A. Gomtsyan, C.-H. Lee, P. Honore, J. P. Sullivan, et al. A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel and Selective Transient Receptor Potential Type V1 Receptor Antagonist, Blocks Channel Activation by Vanilloids, Heat, and Acid J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 400 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Gavva, R. Tamir, Y. Qu, L. Klionsky, T. J. Zhang, D. Immke, J. Wang, D. Zhu, T. W. Vanderah, F. Porreca, et al. AMG 9810 [(E)-3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a Novel Vanilloid Receptor 1 (TRPV1) Antagonist with Antihyperalgesic Properties J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 474 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Gavva, L. Klionsky, Y. Qu, L. Shi, R. Tamir, S. Edenson, T. J. Zhang, V. N. Viswanadhan, A. Toth, L. V. Pearce, et al. Molecular Determinants of Vanilloid Sensitivity in TRPV1 J. Biol. Chem., May 7, 2004; 279(19): 20283 - 20295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Toth, P. M. Blumberg, Z. Chen, and A. P. Kozikowski Design of a High-Affinity Competitive Antagonist of the Vanilloid Receptor Selective for the Calcium Entry-Linked Receptor Population Mol. Pharmacol., February 1, 2004; 65(2): 282 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Pomonis, J. E. Harrison, L. Mark, D. R. Bristol, K. J. Valenzano, and K. Walker N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 387 - 393. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
